44 results about "Antileukemic agent" patented technology

The invention discloses an siRNA inhibiting the PPFIA1 gene expression, and its application. The positive-sense strand sequence of the siRNA is 5'-CCACAAAGCUCUGGAUGAA-3', the antisense strand sequence of the siRNA is 5'-UUCAUCCAGAGCUUUGUGG-3', and dTdT is dangled at the 3' segment of the siRNA seuqnce. The siRNA inhibiting the PPFIA1 gene expression can effectively silence the PPFIA1 gene and provides a technical scheme for researches on the functions of the PPFIA1 gene, and the silenced PPFIA1 gene can inhibit the cell growth and promote the cell apoptosis; and the siRNA can be used for preparing anti-leukemia medicines.

The invention relates to the field of drug synthesis and biological activity evaluation, in particular to an aminomethylpyridine derivative, a preparation method and application thereof. The aminomethylpyridine derivative adopts aminomethylpyridine and substituted benzaldehyde as the raw materials, and the obtained aminomethylpyridine derivative has a general structural formula shown as the specification. The aminomethylpyridine derivative provided by the invention has mild synthesis conditions, and simple and easily operable post-treatment method, thus being suitable for industrial production. Compared with the existing anti-leukemia drug imatinib, the aminomethylpyridine derivative has significant inhibitory effect on human chronic granulocytic leukemia cell line K562, and is suitable for further screening as an anti-leukemia drug.

The invention relates to a dimensional flow liquid phase array detection method of fusion protein in leukemia cells, characterized in that: a microballoon 1 fluorescently labeled by FITC or Alexa Fluor 488 coated by fusion protein capture antibody and a microballoon 2 fluorescently labeled by FITC or Alexa Fluor 488 with another conentration coated by fusion protein capture antibody form a dimensional flow liquid phase array for detecting fusion protein in leukemia cells, after the co-incubation of the microballoon 1, the microballoon 2 , the fusion protein, a reported antibody and / or a secondary antibody fluorescently labeled by PE, a flow cytometry is used for detecting the dimensional flow liquid phase array, and the fusion protein expression value is expressed as a ratio of the PE fluorescence intensity of the microballoon 1 to the PE fluorescence intensity of the microballoon 2. The method can be applied in the biomedicine research fields, such as leukemia pathology, molecular diagnosis, and discovery of anti-leukemic medicines. The method has the advantages of effective elimination of system error, rapidness, and accuracy.

The invention provides the application of a two-dimensional carbon-based nano material for killing leukemia cells. The two-dimensional carbon-based nanomaterials include graphdiyne derivatives such as Graphdiyne (GDY) and Graphdiyne Oxide (GDYO). The leukemia cells are DNMT3A-mutated acute myeloid leukemia (Acute Myeloid Leukemia, AML) cell lines. The GDY and GDYO are nano-sheet structures with a size range of 50nm-500nm. They are added to different types of AML cells cultured in vitro or injected into AML mouse models at a certain dose, which can achieve the effect of targeting only DNMT3A mutant cells. Specific killing, but no obvious effect on normal cells. The invention has great application potential in clinical and scientific research fields such as research and development of anti-leukemia drugs, drug efficacy research and drug resistance research of leukemia cells.

The invention discloses a high-efficiency, targeted drug-loaded nano-micelle and its preparation method and application. The preparation steps are: (1) dissolving the amphiphilic block copolymer in an organic solvent, and then adding a small-molecule anti-leukemia drug Hydrochloride, after fully dissolved and mixed, add triethylamine to remove hydrochloric acid to form a small molecule anti-leukemia drug, and then add it to PBS buffer to form nanomicelles with inner core encapsulated drug and outer shell hydrophilic; after dialysis, dry , to obtain drug-loaded nanomicelles; the polydopamine modification method is used to modify the specific antibody against the leukemia cell surface antigen to achieve targeting. The particle size of the drug-loaded nano-micelle prepared by the invention is 50-100nm, showing good monodispersity, high drug-loading capacity and encapsulation efficiency, simple targeting modification steps, and good targeting leukemia cell killing effect , while for normal cells, it has high biological safety and can achieve slow release, avoiding the disadvantages of long-term and multiple administrations.